美国 · SEC FORM 4
MBX Biosciences, Inc.
MBX · Nasdaq · CIK 0001776111 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
10 同一窗口内观察到的 Form 4 交易行
5 sales · 5 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
—
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2026-03-13 · Hawryluk P. Kent.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 4,466,280
- 上期报告
- 4,129,859
- 日均成交量
- 653,352
- 回补天数
- 6.8
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-03-13 | Hawryluk P. Kent | 买入 (P) | Common Stock | 18,500 | USD 28.41 | USD 525,585 | SEC 申报 ↗ |
| 2025-10-20 | Hawryluk P. Kent | 买入 (P) | Common Stock | 20,000 | USD 13.64 | USD 272,800 | SEC 申报 ↗ |
| 2025-10-17 | Hoerter Steven L. | 买入 (P) | Common Stock | 20,000 | USD 13.25 | USD 265,000 | SEC 申报 ↗ |
| 2025-09-26 | FHMLS X, L.L.C.; FHMLS X, L.P.; Frazier Life Sciences X, L.P.; Heron Patrick J; Topper James N | 买入 (P) | Common Stock | 666,666 | USD 18.00 | USD 11,999,988 | SEC 申报 ↗ |
| 2025-04-08 | Pescovitz Ora H. | 买入 (P) | Common Stock | 7,693 | USD 5.89 | USD 45,312 | SEC 申报 ↗ |
| 2025-02-18 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLC | 买入 (P) | Common Stock | 143,170 | USD 10.84 | USD 1,551,963 | SEC 申报 ↗ |
| 2025-02-18 | GORDON CARL L | 买入 (P) | Common Stock | 143,170 | USD 10.84 | USD 1,551,963 | SEC 申报 ↗ |
| 2025-02-14 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLC | 买入 (P) | Common Stock | 47,502 | USD 9.87 | USD 468,793 | SEC 申报 ↗ |
| 2025-02-14 | GORDON CARL L | 买入 (P) | Common Stock | 47,502 | USD 9.87 | USD 468,793 | SEC 申报 ↗ |
| 2025-02-04 | Hawryluk P. Kent | 买入 (P) | Common Stock | 50,000 | USD 10.69 | USD 534,500 | SEC 申报 ↗ |
| 2024-09-16 | Yang Rick | 买入 (P) | Common Stock | 500,000 | USD 16.00 | USD 8,000,000 | SEC 申报 ↗ |
| 2024-09-16 | Walker Paul Edward | 买入 (P) | Common Stock | 500,000 | USD 16.00 | USD 8,000,000 | SEC 申报 ↗ |
| 2024-09-16 | SANDELL SCOTT D | 买入 (P) | Common Stock | 500,000 | USD 16.00 | USD 8,000,000 | SEC 申报 ↗ |
| 2024-09-16 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLC | 买入 (P) | Common Stock | 750,000 | USD 16.00 | USD 12,000,000 | SEC 申报 ↗ |
| 2024-09-16 | NEA 17 GP, LLC; NEA Partners 17, L.P.; New Enterprise Associates 17, L.P. | 买入 (P) | Common Stock | 500,000 | USD 16.00 | USD 8,000,000 | SEC 申报 ↗ |
Form 4 申报证据
17 transaction lines in the latest 365-day window; 78 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-04 | Azoulay Salomon | 卖出 (S) | Common Stock | 370 | USD 65.77 | USD 24,335 | SEC 申报 ↗ |
| 2026-08-03 | Smither John W | 奖励／授予 (A) | Common Stock | 28,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-03 | Hoerter Steven L. | 奖励／授予 (A) | Common Stock | 71,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
展开近期 Form 4 证据 (15 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-04 | Azoulay Salomon | 卖出 (S) | Common Stock | 370 | USD 65.77 | USD 24,335 | SEC 申报 ↗ |
| 2026-08-03 | Smither John W | 奖励／授予 (A) | Common Stock | 28,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-08-03 | Hoerter Steven L. | 奖励／授予 (A) | Common Stock | 71,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-05-08 | Azoulay Salomon | 卖出 (S) | Common Stock | 70,003 | USD 38.36 | USD 2,685,515 | SEC 申报 ↗ |
| 2026-05-08 | Azoulay Salomon | 期权行权／转换 (M) | Common Stock | 70,003 | USD 11.65 | USD 815,348 | SEC 申报 ↗ |
| 2026-05-06 | Hawryluk P. Kent | 卖出 (S) | Common Stock | 607 | USD 29.54 | USD 17,931 | SEC 申报 ↗ |
| 2026-05-06 | Azoulay Salomon | 卖出 (S) | Common Stock | 231 | USD 29.54 | USD 6,824 | SEC 申报 ↗ |
| 2026-05-01 | Hoerter Steven L. | 奖励／授予 (A) | Common Stock | 11,938 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-13 | Hawryluk P. Kent | 买入 (P) | Common Stock | 18,500 | USD 28.41 | USD 525,585 | SEC 申报 ↗ |
| 2026-02-26 | Hawryluk P. Kent | 期权行权／转换 (M) | Common Stock | 28,768 | USD 16.00 | USD 460,288 | SEC 申报 ↗ |
| 2026-02-02 | Hawryluk P. Kent | 奖励／授予 (A) | Common Stock | 35,250 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-02 | Bartram Richard | 奖励／授予 (A) | Common Stock | 15,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-02-02 | Azoulay Salomon | 奖励／授予 (A) | Common Stock | 15,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-10-24 | Hawryluk P. Kent | 期权行权／转换 (M) | Common Stock | 182,859 | USD 3.25 | USD 594,292 | SEC 申报 ↗ |
| 2025-10-20 | Hawryluk P. Kent | 买入 (P) | Common Stock | 20,000 | USD 13.64 | USD 272,800 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-19 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | MBX |
| CIK | 0001776111 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 78 transaction lines from 2024-09-16 to 2026-08-04 31 P purchase lines · 5 S sale lines · 42 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.